Tuberculosis Therapy
Research conducted by S.I. Zaitzeva and co-researchers has updated our knowledge about tuberculosis therapy
Published in TB and Outbreaks Week, December 15th, 2009
Researchers detail in 'Treatment of cavitary and infiltrating pulmonary tuberculosis with and without the immunomodulator Dzherelo,' new data in tuberculosis. According to a study from Ukraine, "An open-label, 60-day trial was conducted in 75 newly diagnosed tuberculosis (TB) patients to assess the adjunctive effect of the oral immunomodulator Dzherelo with standard anti-TB chemotherapy (ATT) consisting of izoniazid, rifampicin, pyrazinamide and streptomycin (HRZS) administered as directly observed therapy (DOT). Group 1 (n=28) with cavitary TB and group 2 (n=17) with infiltrating pulmonary TB received 50 drops of Dzherelo twice daily in addition to HRZS."
"Group 3...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
More Articles from TB and Outbreaks Week
- Canadian Medical Association Journal
Vaccination, antivirals and social distancing may blunt impact of H1N1 influenza - McGill University Health Centre
Research calls for better assessment of tests for tuberculosis, HIV/AIDS and malaria - McGill University Health Centre
Tuberculosis: On the path to prevention - University of Toronto
Availability of vaccine no guarantee public will want it - Wiley-Blackwell
Transplant infectious disease experts provide pandemic guidance - Anti-Infectives
New anti-infectives study results from S.Y.G. Lin et al described - More from this issue of TB and Outbreaks Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
